

## **Fate Therapeutics to Present at Upcoming Investor Conferences**

SAN DIEGO, Aug. 31, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that Scott Wolchko, President and Chief Executive Officer, will be presenting at two upcoming investor conferences in September:

- | **2016 Wells Fargo Healthcare Conference** at 1:45 p.m. ET on Wednesday, September 7, 2016 in Boston.
- | **Rodman & Renshaw 18<sup>th</sup> Annual Global Investment Conference** at 11:15 a.m. ET on Tuesday, September 13, 2016 in New York City.

Live webcasts of the presentations will be available through the investor relations section of the Company's website at [www.fatetherapeutics.com](http://www.fatetherapeutics.com). Following the live webcasts, archived replays of each presentation will be available on the Company's website for 30 days after the respective conference.

### **About Fate Therapeutics, Inc.**

Fate Therapeutics is a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders. The Company's cell therapy pipeline is comprised of immuno-oncology programs, including off-the-shelf NK- and T-cell cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for regulating autoimmunity. Its adoptive cell therapy programs are based on the Company's novel ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit [www.fatetherapeutics.com](http://www.fatetherapeutics.com).

#### Contact:

Jesse Baumgartner  
Stern Investor Relations, Inc.  
212.362.1200  
[jesse@sternir.com](mailto:jesse@sternir.com)